| Target Price | $4.08 |
| Price | $0.45 |
| Potential |
796.90%
register free of charge
|
| Number of Estimates | 3 |
|
3 Analysts have issued a price target Vaxart, Inc. 2027 .
The average Vaxart, Inc. target price is $4.08.
This is
796.90%
register free of charge
$4.20
823.28%
register free of charge
$4.04
788.11%
register free of charge
|
|
| A rating was issued by 9 analysts: 8 Analysts recommend Vaxart, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Vaxart, Inc. stock has an average upside potential 2027 of
796.90%
register free of charge
|
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 237.26 | 204.46 |
| 726.69% | 13.82% | |
| Net Margin | 6.88% | -8.06% |
| 102.95% | 217.10% |
4 Analysts have issued a sales forecast Vaxart, Inc. 2026 . The average Vaxart, Inc. sales estimate is
This results in the following potential growth metrics:
4 Vaxart, Inc. Analysts have issued a net profit forecast 2026. The average Vaxart, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 0.07 | -0.07 |
| 121.21% | 200.00% | |
| P/E | negative |
4 Analysts have issued a Vaxart, Inc. forecast for earnings per share. The average Vaxart, Inc. EPS is
This results in the following potential growth metrics and future valuations:
| Analyst | Rating | Action | Date |
|---|---|---|---|
| B. Riley Securities |
Locked
➜
Locked
|
Locked | Mar 27 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
B. Riley Securities:
Locked
➜
Locked
|
Mar 27 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


